RBL2 and lung cancer: Moreover, we developed a 39-residue peptide, called Spa310, derived from the spacer region of RBL2/p130, which was able to inhibit CDK2 activity and lung cancer proliferation in xenotrasplanted nude mice, thus suggesting that this peptide could represent the basis for the development of new targeted therapeutic strategies [146–148].